Weight Loss & Metabolic Health

The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.

The once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

Investigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.

Investigational glucagon / GLP-1 dual agonist from Boehringer Ingelheim — Phase 3 for obesity and MASH.

A glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved.

Long-acting amylin analog — Novo Nordisk’s answer to GLP-1 from a second satiety pathway, studied alone and as half of CagriSema. Phase 3 monotherapy reported ~11.8% mean weight loss.

Novo Nordisk’s fixed once-weekly combination of cagrilintide (amylin) + semaglutide (GLP-1) — 20.4%–22.7% mean weight loss in Phase 3, filed with the FDA in December 2025.

The archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.

Insulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.

GHRH analog FDA-approved for HIV-associated lipodystrophy.

An anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.

A "sweeping" anti-myostatin antibody (Roche/Chugai) that not only blocks but actively clears myostatin — a cautionary case after its rare-disease trials failed.

An anti-activin-A antibody (Regeneron) — the first drug on the whole activin/myostatin axis to reach FDA approval (as Pasatru, for the rare bone disease FOP), and the activin-A leg of obesity muscle-preservation combinations.

An antibody that blocks the activin type II receptor itself — shutting off myostatin AND activin signaling at once; famous for adding muscle while cutting fat.

Mitochondrially-encoded peptide with reported insulin-sensitizing activity.

A 24-amino-acid mitochondrial-derived peptide with cytoprotective, anti-apoptotic activity — a companion to MOTS-c on the mitochondrial-signaling frontier.

Synthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.

The lipolytic C-terminal fragment of human growth hormone — the parent peptide that AOD-9604 was engineered from.

C-terminal hGH fragment (177–191) historically investigated for lipolysis.

A fat-targeting proapoptotic peptide that destroys the blood supply of white fat — striking in animals, but discontinued in humans for kidney toxicity.

Small-molecule NNMT inhibitor (often catalogued alongside peptides).

The pancreas’s second satiety hormone — co-secreted with insulin from the beta cell; its stabilized analog pramlintide treats diabetes, and the class now drives a new wave of obesity drugs.

The stabilized amylin analog — three prolines that stop native amylin from aggregating, turning the beta cell’s second satiety hormone into an injectable diabetes drug.